INSIGHT REPORT CALENDAR

NEWSLETTER

Like this article?

Sign up to our free newsletter

Arlington Capital acquires avian vaccine firm

Washington DC-based private equity firm Arlington Capital Partners has acquired Charles River Laboratories’ Avian Vaccine Services business to form a new company, AVS Bio. 

Washington DC-based private equity firm Arlington Capital Partners (Arlington) has acquired Charles River Laboratories’ Avian Vaccine Services business to form a new company, AVS Bio. 

The new company, which will operate independently as a standalone platform for Arlington, will serve the biologic manufacturing and bioprocessing markets.

AVS Bio is a provider of specific pathogen free (SPF) eggs and adjacent laboratory products and services that support the development and manufacture of vaccines, therapeutics, and other biologics used for human and animal health. The company supplies leading manufacturers with critical bioprocessing inputs including SPF eggs, antigens, and cell products. 

It also provides diagnostic testing and manufacturing support services and supports new therapeutic development through supplying antibodies such as IgY for use in clinical trials. Headquartered in Norwich, CT, the Company has ~250 employees across over 20 facilities located in the US and Europe.
 

Like this article? Sign up to our free newsletter

FEATURED

Tech Stocks

MOST RECENT

FURTHER READING